RA
LCTX icon

Reby Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Reby Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$3K Buy
+1,775
New +$2.48K ﹤0.01% 529

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Reby Advisors's LCTX Position: Q4 2020 in Review

Reby Advisors opened a new position in Lineage Cell Therapeutics (LCTX) in Q4 2020: 1,775 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #529 among its holdings.

89 funds tracked by Wall St. Rank hold LCTX as of Q4 2020.

  • Reby Advisors held 1,775 shares of Lineage Cell Therapeutics worth $3K as of Q4 2020.
  • Lineage Cell Therapeutics was a new Reby Advisors position in Q4 2020.
  • Lineage Cell Therapeutics made up ﹤0.01% of Reby Advisors's portfolio in Q4 2020, its #529 holding.
  • 89 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2020.

Based on Reby Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.